The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Patients with metabolic syndrome, insulin resistance, and elevated triglycerides of 150 mg/dl
or higher will be randomized to one of four groups: 1) placebo; 2) metformin; 3) fenofibrate;
or 4) combined metformin and fenofibrate for a period of 12 weeks after titration to target
dose. We are interested in the effects of these therapies on triglyceride levels, HDL-C,
insulin resistance, and markers of inflammation.